Post by Organon

Intended for US audiences only. Organon has completed a global licensing agreement with Sebela Pharmaceuticals for their contraceptive product, expanding Organon’s portfolio of long-acting reversible contraception options. This agreement underscores our commitment to broadening contraceptive choice and delivering options that meet women’s needs. By building on our legacy in contraception, we continue to focus on expanding access to important options that support women’s health. Learn more: https://ogn.llc/6047vWW6d